Shionogi's Anti-Obesity Drug S-2367 Phase IIb Shows Promising Results
This article was originally published in PharmAsia News
Executive Summary
Shionogi announced May 13 that a Phase IIb analysis of anti-obesity drug S-2367 showed good results in both reduced calorie and low calorie tests. Following the analysis, Shionogi decided to continue the trials and plans to start Phase III trials during the second half of next year. Shionogi considers S-2367, which is being developed in the U.S., as one of its major products to expand overseas. Shionogi plans to obtain approval for the drug in 2011 and market it in 2013. The company is also looking for other companies to jointly develop and market the product. (Click here for more - Japanese language
You may also be interested in...
Shionogi Reports Successful Phase II Results For Obesity Treatment Velneperit; Analysts Lukewarm
TOKYO - Osaka-based antibiotics manufacturer Shionogi reported positive results and "significant reduction in body weight" for its Phase II velneperit trial for obesity, but analysts were lukewarm about the results
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.